499 Illinois Street
Suite 500
San Francisco, CA 94158
United States
415 906 4324
http://www.vir.bio
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 297
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. George A. Scangos | Pres, CEO & Director | 785.83k | N/A | 1948 |
Dr. Klaus Frueh | Co-Founder & Scientific Advisor | 177.66k | N/A | 1960 |
Mr. Howard Horn | CFO & Sec. | 599.25k | N/A | 1977 |
Dr. Herbert W. Virgin IV | Exec. VP of Research & Chief Scientific Officer | 949.9k | N/A | 1956 |
Dr. Jay Parrish | Co-Founder & Chief Bus. Officer | N/A | N/A | 1975 |
Dr. Lawrence Corey | Co-Founder & Scientific Advisor | N/A | N/A | N/A |
Dr. Louis J. Picker | Co-Founder & Scientific Advisor | N/A | N/A | N/A |
Dr. Michael E. Kamarck | Chief Technology Officer | N/A | N/A | 1951 |
Mr. Steven J. Rice | Chief Admin. Officer | N/A | N/A | N/A |
Dr. Neera Dahiya Ravindran M.D., MBA | VP and Head of Investor Relations & Strategic Communications | N/A | N/A | N/A |
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc.’s ISS governance QualityScore as of 2 December 2020 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 9; Compensation: 9.